Neurocrine Biosciences Stock EBITDA

NBIX Stock

USD 125.00 1.71 1.39%

Neurocrine Biosciences fundamentals help investors to digest information that contributes to Neurocrine Biosciences' financial success or failures. It also enables traders to predict the movement of Neurocrine Stock. The fundamental analysis module provides a way to measure Neurocrine Biosciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Neurocrine Biosciences stock.

		Last Reported	Projected for Next Year
	EBITDA	416.1 M	436.9 M

EBITDA is likely to rise to about 436.9 M in 2024.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Neurocrine Biosciences Company EBITDA Analysis

Neurocrine Biosciences' EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

EBITDA

Revenue

-

Basic Expenses

More About EBITDA | All Equity Analysis

Current Neurocrine Biosciences EBITDA

416.1 M

Most of Neurocrine Biosciences' fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Neurocrine Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Neurocrine EBITDA Driver Correlations

Understanding the fundamental principles of building solid financial models for Neurocrine Biosciences is extremely important. It helps to project a fair market value of Neurocrine Stock properly, considering its historical fundamentals such as EBITDA. Since Neurocrine Biosciences' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Neurocrine Biosciences' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Neurocrine Biosciences' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Short Term Investments	Long Term Debt	Common Stock	Property Plant Equipment	Current Deferred Revenue	Net Tangible Assets	Capital Surpluse	Deferred Long Term Liab	Long Term Investments	Long Term Debt Total	Net Invested Capital	Short Long Term Debt	Net Working Capital	Capital Stock
Total Assets		0.99	0.39	0.47	0.98	0.97	0.96	0.99	0.57	0.87	0.93	0.79	0.58	0.91	0.77	0.97	0.84	0.54	0.97	-0.8	0.62	-0.72	0.77	0.92
Total Stockholder Equity	0.99		0.32	0.54	0.98	0.99	0.91	0.97	0.52	0.87	0.9	0.71	0.55	0.88	0.82	0.99	0.81	0.5	0.95	-0.85	0.6	-0.71	0.8	0.94
Net Debt	0.39	0.32		-0.03	0.43	0.38	0.5	0.41	0.74	0.13	0.41	0.57	0.21	0.43	0.32	0.23	0.39	0.31	0.49	0.15	0.09	-0.17	-0.05	0.19
Retained Earnings	0.47	0.54	-0.03		0.54	0.58	0.3	0.39	0.08	0.48	0.27	0.01	-0.29	0.36	0.65	0.54	0.1	0.2	0.46	-0.68	0.33	-0.27	0.55	0.63
Accounts Payable	0.98	0.98	0.43	0.54		0.98	0.93	0.95	0.65	0.84	0.9	0.72	0.48	0.87	0.81	0.93	0.77	0.5	0.96	-0.78	0.63	-0.62	0.7	0.93
Net Receivables	0.97	0.99	0.38	0.58	0.98		0.89	0.96	0.59	0.83	0.9	0.68	0.48	0.85	0.88	0.96	0.76	0.47	0.93	-0.81	0.54	-0.65	0.77	0.93
Total Liab	0.96	0.91	0.5	0.3	0.93	0.89		0.96	0.66	0.83	0.92	0.92	0.6	0.92	0.64	0.87	0.86	0.6	0.94	-0.65	0.63	-0.71	0.64	0.83
Total Current Assets	0.99	0.97	0.41	0.39	0.95	0.96	0.96		0.61	0.86	0.97	0.83	0.63	0.92	0.76	0.95	0.88	0.57	0.93	-0.74	0.53	-0.74	0.76	0.88
Short Term Debt	0.57	0.52	0.74	0.08	0.65	0.59	0.66	0.61		0.37	0.67	0.64	0.35	0.58	0.4	0.38	0.53	0.41	0.57	-0.07	0.25	-0.12	0.03	0.41
Intangible Assets	0.87	0.87	0.13	0.48	0.84	0.83	0.83	0.86	0.37		0.79	0.67	0.48	0.9	0.6	0.88	0.73	0.64	0.78	-0.78	0.55	-0.77	0.81	0.82
Short Term Investments	0.93	0.9	0.41	0.27	0.9	0.9	0.92	0.97	0.67	0.79		0.83	0.65	0.89	0.69	0.86	0.86	0.59	0.84	-0.62	0.47	-0.72	0.69	0.79
Long Term Debt	0.79	0.71	0.57	0.01	0.72	0.68	0.92	0.83	0.64	0.67	0.83		0.63	0.85	0.39	0.67	0.84	0.63	0.77	-0.38	0.46	-0.67	0.48	0.59
Common Stock	0.58	0.55	0.21	-0.29	0.48	0.48	0.6	0.63	0.35	0.48	0.65	0.63		0.58	0.23	0.55	0.87	0.44	0.51	-0.3	0.45	-0.53	0.49	0.49
Property Plant Equipment	0.91	0.88	0.43	0.36	0.87	0.85	0.92	0.92	0.58	0.9	0.89	0.85	0.58		0.54	0.86	0.87	0.69	0.84	-0.61	0.53	-0.79	0.7	0.77
Current Deferred Revenue	0.77	0.82	0.32	0.65	0.81	0.88	0.64	0.76	0.4	0.6	0.69	0.39	0.23	0.54		0.81	0.49	0.23	0.75	-0.76	0.28	-0.49	0.72	0.8
Net Tangible Assets	0.97	0.99	0.23	0.54	0.93	0.96	0.87	0.95	0.38	0.88	0.86	0.67	0.55	0.86	0.81		0.8	0.46	0.91	-0.89	0.56	-0.76	0.87	0.93
Capital Surpluse	0.84	0.81	0.39	0.1	0.77	0.76	0.86	0.88	0.53	0.73	0.86	0.84	0.87	0.87	0.49	0.8		0.64	0.78	-0.52	0.57	-0.7	0.68	0.74
Deferred Long Term Liab	0.54	0.5	0.31	0.2	0.5	0.47	0.6	0.57	0.41	0.64	0.59	0.63	0.44	0.69	0.23	0.46	0.64		0.46	-0.25	0.44	-0.58	0.47	0.48
Long Term Investments	0.97	0.95	0.49	0.46	0.96	0.93	0.94	0.93	0.57	0.78	0.84	0.77	0.51	0.84	0.75	0.91	0.78	0.46		-0.76	0.69	-0.64	0.67	0.91
Long Term Debt Total	-0.8	-0.85	0.15	-0.68	-0.78	-0.81	-0.65	-0.74	-0.07	-0.78	-0.62	-0.38	-0.3	-0.61	-0.76	-0.89	-0.52	-0.25	-0.76		-0.58	0.61	-0.86	-0.89
Net Invested Capital	0.62	0.6	0.09	0.33	0.63	0.54	0.63	0.53	0.25	0.55	0.47	0.46	0.45	0.53	0.28	0.56	0.57	0.44	0.69	-0.58		-0.45	0.46	0.76
Short Long Term Debt	-0.72	-0.71	-0.17	-0.27	-0.62	-0.65	-0.71	-0.74	-0.12	-0.77	-0.72	-0.67	-0.53	-0.79	-0.49	-0.76	-0.7	-0.58	-0.64	0.61	-0.45		-0.85	-0.65
Net Working Capital	0.77	0.8	-0.05	0.55	0.7	0.77	0.64	0.76	0.03	0.81	0.69	0.48	0.49	0.7	0.72	0.87	0.68	0.47	0.67	-0.86	0.46	-0.85		0.82
Capital Stock	0.92	0.94	0.19	0.63	0.93	0.93	0.83	0.88	0.41	0.82	0.79	0.59	0.49	0.77	0.8	0.93	0.74	0.48	0.91	-0.89	0.76	-0.65	0.82

Click cells to compare fundamentals

In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.

Competition

Predict Neurocrine Biosciences

Ebitda Over Time

Neurocrine Ebitda

Ebitda

436.9 Million

At this time, Neurocrine Biosciences' EBITDA is fairly stable compared to the past year.

According to the company disclosure, Neurocrine Biosciences reported earnings before interest,tax, depreciation and amortization of 416.1 M. This is 52.58% lower than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The ebitda for all United States stocks is 89.33% higher than that of the company.

Neurocrine EBITDA Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Neurocrine Biosciences' direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Neurocrine Biosciences could also be used in its relative valuation, which is a method of valuing Neurocrine Biosciences by comparing valuation metrics of similar companies.

Neurocrine Biosciences is currently under evaluation in ebitda category among its peers.

Neurocrine Biosciences ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Neurocrine Biosciences' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Neurocrine Biosciences' managers, analysts, and investors.

Environmental

Governance

Social

Neurocrine Biosciences Institutional Holders

Institutional Holdings refers to the ownership stake in Neurocrine Biosciences that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Neurocrine Biosciences' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Neurocrine Biosciences' value.

		Shares
Aqr Capital Management Llc	2024-06-30	1.2 M
Goldman Sachs Group Inc	2024-06-30	1.1 M
Armistice Capital, Llc	2024-06-30	978.5 K
Hhg Plc	2024-06-30	971.2 K
Dsm Capital Partners Llc	2024-09-30	944.2 K
Brown Advisory Holdings Inc	2024-09-30	942.1 K
Rock Springs Capital Management Lp	2024-06-30	940 K
Bank Of New York Mellon Corp	2024-06-30	934.4 K
Braidwell Lp	2024-09-30	917.7 K
Blackrock Inc	2024-06-30	14.2 M
Vanguard Group Inc	2024-09-30	10 M

Neurocrine Fundamentals

	Return On Equity	0.16
	Return On Asset	0.12
	Profit Margin	0.17 %
	Operating Margin	0.30 %
	Current Valuation	11.51 B
	Shares Outstanding	101.25 M
	Shares Owned By Insiders	0.99 %
	Shares Owned By Institutions	95.49 %
	Number Of Shares Shorted	2.48 M
	Price To Earning	202.90 X
	Price To Book	4.59 X
	Price To Sales	5.64 X
	Revenue	1.89 B
	Gross Profit	1 B
	EBITDA	416.1 M
	Net Income	249.7 M
	Cash And Equivalents	799.4 M
	Cash Per Share	8.31 X
	Total Debt	428.4 M
	Debt To Equity	0.18 %
	Current Ratio	2.48 X
	Book Value Per Share	26.87 X
	Cash Flow From Operations	389.9 M
	Short Ratio	2.86 X
	Earnings Per Share	3.75 X
	Price To Earnings To Growth	0.29 X
	Target Price	163.46
	Number Of Employees	1.7 K
	Beta	0.35
	Market Capitalization	12.66 B
	Total Asset	3.25 B
	Retained Earnings	(157.1 M)
	Working Capital	952.2 M
	Current Asset	384.07 M
	Current Liabilities	25.71 M
	Net Asset	3.25 B

About Neurocrine Biosciences Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Neurocrine Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Neurocrine Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Neurocrine Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for Neurocrine Stock Analysis

When running Neurocrine Biosciences' price analysis, check to measure Neurocrine Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neurocrine Biosciences is operating at the current time. Most of Neurocrine Biosciences' value examination focuses on studying past and present price action to predict the probability of Neurocrine Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neurocrine Biosciences' price. Additionally, you may evaluate how the addition of Neurocrine Biosciences to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC